Scientific Poster Session I: Late-Breaking Original Research

Abstract

The National Institutes of Health (NIH) guidelines currently do not offer clear guidance on remdesivir treatment duration in hospitalized patients with COVID-19.

Research Question or Hypothesis:

Does a 3-day course of remdesivir (3RDV) provide similar efficacy to a 5-day course (5RDV) in hospitalized patients with COVID-19?

Study Design:

We conducted a single-center, retrospective cohort study evaluating outcomes in adult patients admitted to the hospital in 2022, who received at least 1 dose of remdesivir for COVID-19 treatment.

Methods:

The study's main objective was to determine if a 3RDV affected the 30-day readmission rate compared to a 5RDV. We also sought to determine if the need for supplemental oxygen on admission could help risk stratify patients for 3 vs. 5 days of remdesivir in otherwise matched patients. Other secondary outcomes included length of stay (LOS) and all-cause 30-day mortality.

Results:

Overall, 402 patients were included in this study; mean age was 78 years and 50% were male. All baseline characteristics between both groups were well balanced, except for the baseline oxygen requirement (1L vs. 4L, p<0.001).

There was no increase in 30-day hospital readmission rates between a 3RDV and a 5RDV (14% vs. 24%, p=0.004). Patients who received a 3RDV also had shorter LOS (3.1 days vs. 5.2 days, p<0.001) without negative outcomes on all-cause mortality rate (4% vs 8%, p=0.113). Similar results were found in patients with severe COVID-19 requiring less than 2L of supplemental oxygen.

Conclusion:

This study demonstrated that a 3RDV was not associated with increased 30-day readmission rate in patients at high risk for severe COVID-19 disease with low-to-no (= 1L) supplemental oxygen requirement on admission. Supplemental oxygen need at the time of COVID-19 admission was found to be a useful tool in selecting a 3 vs. 5-day course of remdesivir.

Presenting Author

Authors